Q-omics provides the consensus-scored SPTB profile across patient tissues and cancer cell-line models. SPTB expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPTB is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SPTB protein abundance shows 22,823 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, KIRC, and CCRCC as cancer lineages where SPTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTB survival associations across molecular data types. SPTB RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTB RNA expression–survival associations across cancer types. High SPTB expression shows unfavorable associations in UVM, UCEC and BLCA, but favorable associations in PAAD, ACC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPTB RNA expression.
This table summarizes SPTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SPTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTB shows lower tumor expression in KIRC, KICH, KIRP and BRCA and higher tumor expression in LUAD and BLCA. The KIRC box plot shows higher SPTB RNA expression in normal versus tumor tissue (log2 FC = −1.221, t-test p < 0.001).
This table shows molecular features associated with SPTB in patient tissues and cancer cell lines. In patient samples, SPTB shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
